Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735512 · ClinicalTrials.gov registry record
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 10
- Enrollment target
NCT02735512 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 10 participants.
The verdict
NCT02735512 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This pilot research trial studies how well myeloid derived suppressor cells (MDSC) clinical assay works in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic bladder cancer. Studying samples of blood and urine from patients with or without bladder cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer and may help doctors improve ways to diagnose and treat patients.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2022-04-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02735512
The ClinicalTrials.gov registry entry for NCT02735512 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02735512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02735512 about?
NCT02735512 is a clinical study titled "MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer". This pilot research trial studies how well myeloid derived suppressor cells (MDSC) clinical assay works in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic bladder cancer. Studying samples of blood and urine from patients with or wi...
What is the current status of trial NCT02735512?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2016-03-01. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT02735512?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02735512?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.